We analyzed expression of Icsbp and Gas2 in these cells to determine if either Shp2 inhibition or Calpain activation might be a rationale therapeutic approach to CML (Figure 6B). This evidence concerns the gene GAS2 and chronic myelogenous leukemia, BCR-ABL1 positive.